By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cyclacel Pharmaceuticals, Inc. 

200 Connell Drive
Suite 1500
Berkeley Heights  New Jersey  07922  U.S.A.
Phone: 908-517-7330 Fax: 866-271-3466


Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.




Founder: Sir David Lane

CEO: Spiro Rombotis


Please click here for Cyclacel job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Cyclacel Pharma
Symbol: CYCC

Company News
Cyclacel Pharma (CYCC) Announces Pricing Of $13.2 Million Underwritten Public Offering 7/19/2017 8:23:25 AM
Cyclacel Pharma (CYCC) Reports First Quarter 2017 Financial Results 5/12/2017 7:48:57 AM
Cyclacel Pharma (CYCC) To Release First Quarter 2017 Financial Results 5/5/2017 8:43:52 AM
Cyclacel Pharma (CYCC) Presents Identification Of Sensitive Target Indications And Synergistic Drug Combinations For Novel PLK1 Inhibitor CYC140 4/5/2017 11:19:56 AM
Cyclacel Pharma (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects In Lung Cancer By Engaging Anti-Metastatic Pathways 4/3/2017 7:35:45 AM
Cyclacel Pharma (CYCC) Reports Fourth Quarter And Full Year 2016 Financial Results 3/29/2017 9:26:39 AM
Cyclacel Pharma (CYCC) To Release Fourth Quarter And Full Year 2016 Financial Results 3/21/2017 9:05:08 AM
Cyclacel Pharma (CYCC)’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, A Novel Cancer-Specific Mechanism Of Action, In Research Published In JNCI 3/7/2017 8:31:13 AM
Cyclacel Pharma (CYCC) Crashes as Leukemia Drug Flunks Key Late-Stage Trial 2/23/2017 5:38:38 AM
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia 12/1/2016 7:12:53 AM